RecruitingPhase 4NCT07219121

Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

Studying Nephrotic syndrome without extrarenal manifestations

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Travere Therapeutics, Inc.
Principal Investigator
Radko Komers, MD, PhD
Travere Therapeutics
Intervention
Sparsentan(drug)
Enrollment
20 enrolled
Eligibility
18 years · All sexes
Timeline
20252027

Study locations (9)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07219121 on ClinicalTrials.gov

Other trials for Nephrotic syndrome without extrarenal manifestations

Additional recruiting or active studies for the same condition.

See all trials for Nephrotic syndrome without extrarenal manifestations

← Back to all trials